FLOVID-20 / Flow Pharma - LARVOL DELTA

Flow Pharma announces start of pre-clinical efficacy study for FlowVax Covid-19 vaccine (Issuer Direct) - "Flow Pharma, Inc....today announced that researchers at the University of Texas Medical Branch at Galveston (UTMB) will begin testing Flow Pharma's FlowVax COVID-19 vaccine candidate by challenging nonhuman primates with SARS-CoV-2, the virus that causes COVID-19 in humans, after the animals are vaccinated this month with FlowVax COVID-19. FlowVax vaccines utilize Flow Pharma's patented Size Exclusion Antigen Presentation Control (SEAPAC(TM)) technology based on the benefits of making vaccine microspheres the same size as human white blood cells."

Preclinical